Korsana Biosciences, Inc. (KRSA)
| Market Cap | 1.48B +20,552.7% |
| Revenue (ttm) | n/a |
| Net Income | -49.08M |
| EPS | -13.37 |
| Shares Out | 45.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 129,773 |
| Open | 30.49 |
| Previous Close | 31.03 |
| Day's Range | 29.78 - 32.92 |
| 52-Week Range | 7.19 - 59.36 |
| Beta | 1.73 |
| Analysts | Strong Buy |
| Price Target | 44.00 (+35.22%) |
| Est. Earnings | Nov 11, 2026 |
About KRSA
Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead product candidat... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for KRSA stock is "Strong Buy." The 12-month stock price target is $44.0, which is an increase of 35.22% from the latest price.
News
Korsana Biosciences Proxy statement: Proxy filing
Korsana Biosciences filed a proxy statement on October 15, 2026, providing details for shareholder voting and corporate governance matters.
Korsana Biosciences initiated with a Buy at Guggenheim on KRSA-028 potential
As previously reported, Guggenheim analyst Yatin Suneja initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and $70 price target. KRSA-028 is a second-generation monoclonal antibody del...
Korsana Biosciences Proxy statement: Proxy filing
Korsana Biosciences filed a proxy statement on October 5, 2026, providing details for shareholder voting and corporate governance matters.
Wedbush starts Korsana at Outperform on Alzheimer’s potential
Wedbush analyst Laura Chico initiated coverage of Korsana Biosciences (KRSA) with an Outperform rating and $44 price target The firm believes the company’s next-generation anti-amyloid-C KRSA-028 offe...
Korsana Biosciences initiated with an Outperform at Wedbush
Wedbush analyst Laura Chico initiated coverage of Korsana Biosciences (KRSA) with an Outperform rating and $44 price target
Korsana Biosciences initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and $70 price target KRSA-028 is a second-generation shuttled anti-Abeta monoclonal antibody built on the proprietary THET...
Korsana Biosciences initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and $70 price target
Korsana Biosciences initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and no price target The firm believes the company has the superior brain shuttle technology for Alzheimer’s disease.
Korsana Biosciences initiated with a Buy at Stifel
Stifel initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and $43 price target Korsana is a neuroscience focused biotech company that is pioneering the advancement of multiple drug…
UBS starts Korsana Biosciences at Buy on Alzheimer’s potential
UBS last night initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and $55 price target The firm views the company’s lead asset KRSA-028 as a potential “best-in-class” treatment…
Korsana Biosciences initiated with a Buy at UBS
UBS initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and $55 price target
Korsana Biosciences Slides: Corporate presentation
Korsana Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Korsana Biosciences Quarterly report: Q2 2026
Korsana Biosciences has published its Q2 2026 quarterly earnings report on August 4, 2026.
Korsana Biosciences Quarterly report: Q1 2026
Korsana Biosciences has published its Q1 2026 quarterly earnings report on May 12, 2026.
Korsana Biosciences Transcript: M&A announcement
The all-stock merger pairs a ~$380 million private placement with KRSA-028 development, with cash runway expected into 2029. The program targets key clinical readouts in 2027, subject to merger approval and completion.
Korsana Biosciences Press release: M&A announcement
Korsana Biosciences issued a press release on April 1, 2026, disclosing material business information to investors.
Korsana Biosciences Annual report: Q4 2025
Korsana Biosciences has published its Q4 2025 annual report on March 30, 2026.
Korsana Biosciences Quarterly report: Q3 2025
Korsana Biosciences has published its Q3 2025 quarterly earnings report on November 12, 2025.